By LabPulse.com staff writers

October 9, 2019 -- Sekisui Diagnostics announced that its Acucy influenza A and B test has received 510(k) clearance and CLIA waiver from the U.S. Food and Drug Administration (FDA).

The test is designed for use with the company's Acucy point-of-care reader, which Sekisui said can be used to test nasal and nasopharyngeal swabs onsite as well as in laboratory settings. Sekisui announced the clearance on October 8, following an FDA decision on December 17, 2018.

Sekisui also markets the Osom Ultra (manual read lateral flow) and Silaris molecular point-of-care tests for influenza A and B.

Applied BioCode files 510(k) for respiratory pathogen panel
Applied BioCode has submitted its Respiratory Pathogen Panel, which detects viruses and bacteria that cause upper respiratory infections, for 510(k) clearance...
ELISA blood test helps identify flu immunity
Researchers used an enzyme-linked immunosorbent assay (ELISA) blood test to assess immune response in people exposed to the H1N1 influenza A virus and...
InDevR's flu assay gets green light from FDA
InDevR's FluChip-8G Influenza A+B assay -- designed to identify virus subtypes -- has received 510(k) marketing clearance from the U.S. Food and Drug...

Copyright © 2019 LabPulse.com

Last Updated eh 10/9/2019 2:47:20 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email